Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Cash & Equivalents (2024 - 2025)

BioAge Labs (BIOA) has disclosed Cash & Equivalents for 2 consecutive years, with $188.9 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 46.69% to $188.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $188.9 million through Dec 2025, down 46.69% year-over-year, with the annual reading at $188.9 million for FY2025, 46.69% down from the prior year.
  • Cash & Equivalents hit $188.9 million in Q4 2025 for BioAge Labs, down from $215.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $354.3 million in Q4 2024 to a low of $174.0 million in Q1 2024.